ATXS
Price
$5.21
Change
+$0.01 (+0.19%)
Updated
Apr 24 closing price
Capitalization
294.02M
13 days until earnings call
STRO
Price
$1.30
Change
+$0.40 (+44.44%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
108.91M
24 days until earnings call
Ad is loading...

ATXS vs STRO

Header iconATXS vs STRO Comparison
Open Charts ATXS vs STROBanner chart's image
Astria Therapeutics
Price$5.21
Change+$0.01 (+0.19%)
Volume$1.4M
Capitalization294.02M
Sutro Biopharma
Price$1.30
Change+$0.40 (+44.44%)
Volume$179.25K
Capitalization108.91M
ATXS vs STRO Comparison Chart
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. STRO commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a StrongBuy and STRO is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (ATXS: $5.21 vs. STRO: $1.30)
Brand notoriety: ATXS and STRO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 399% vs. STRO: 242%
Market capitalization -- ATXS: $294.02M vs. STRO: $108.91M
ATXS [@Biotechnology] is valued at $294.02M. STRO’s [@Biotechnology] market capitalization is $108.91M. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileSTRO’s FA Score has 1 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • STRO’s FA Score: 1 green, 4 red.
According to our system of comparison, STRO is a better buy in the long-term than ATXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 4 TA indicator(s) are bullish while STRO’s TA Score has 5 bullish TA indicator(s).

  • ATXS’s TA Score: 4 bullish, 4 bearish.
  • STRO’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, STRO is a better buy in the short-term than ATXS.

Price Growth

ATXS (@Biotechnology) experienced а +28.96% price change this week, while STRO (@Biotechnology) price change was +147.81% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.06%. For the same industry, the average monthly price growth was -5.30%, and the average quarterly price growth was -11.62%.

Reported Earning Dates

ATXS is expected to report earnings on Aug 11, 2025.

STRO is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+8.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATXS($294M) has a higher market cap than STRO($109M). STRO YTD gains are higher at: -29.348 vs. ATXS (-41.723). ATXS has higher annual earnings (EBITDA): -111.56M vs. STRO (-186.81M). ATXS (328M) and STRO (317M) have equal amount of cash in the bank . ATXS has less debt than STRO: ATXS (5.35M) vs STRO (23.2M). STRO has higher revenues than ATXS: STRO (62M) vs ATXS (0).
ATXSSTROATXS / STRO
Capitalization294M109M270%
EBITDA-111.56M-186.81M60%
Gain YTD-41.723-29.348142%
P/E RatioN/AN/A-
Revenue062M-
Total Cash328M317M103%
Total Debt5.35M23.2M23%
FUNDAMENTALS RATINGS
ATXS vs STRO: Fundamental Ratings
ATXS
STRO
OUTLOOK RATING
1..100
2675
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
31
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9498
PRICE GROWTH RATING
1..100
9194
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

STRO's Valuation (31) in the Pharmaceuticals Major industry is in the same range as ATXS (61) in the Biotechnology industry. This means that STRO’s stock grew similarly to ATXS’s over the last 12 months.

STRO's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as ATXS (100) in the Biotechnology industry. This means that STRO’s stock grew similarly to ATXS’s over the last 12 months.

ATXS's SMR Rating (94) in the Biotechnology industry is in the same range as STRO (98) in the Pharmaceuticals Major industry. This means that ATXS’s stock grew similarly to STRO’s over the last 12 months.

ATXS's Price Growth Rating (91) in the Biotechnology industry is in the same range as STRO (94) in the Pharmaceuticals Major industry. This means that ATXS’s stock grew similarly to STRO’s over the last 12 months.

ATXS's P/E Growth Rating (100) in the Biotechnology industry is in the same range as STRO (100) in the Pharmaceuticals Major industry. This means that ATXS’s stock grew similarly to STRO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSSTRO
RSI
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 2 days ago
86%
MACD
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 2 days ago
80%
Declines
ODDS (%)
Bearish Trend 9 days ago
90%
Bearish Trend 8 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 2 days ago
79%
Aroon
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Ad is loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LRCX70.904.17
+6.25%
Lam Research Corp
NE20.790.83
+4.16%
Noble Corp
LPG20.980.56
+2.74%
DORIAN LPG Ltd
IKNA1.21N/A
N/A
Ikena Oncology
CTO17.99-0.15
-0.83%
CTO Realty Growth

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with TRDA. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
+0.19%
TRDA - ATXS
52%
Loosely correlated
+2.87%
KYMR - ATXS
52%
Loosely correlated
+9.32%
XENE - ATXS
49%
Loosely correlated
+1.62%
APGE - ATXS
49%
Loosely correlated
+1.42%
DNLI - ATXS
49%
Loosely correlated
+4.17%
More

STRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, STRO has been loosely correlated with ATXS. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if STRO jumps, then ATXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STRO
1D Price
Change %
STRO100%
+44.44%
ATXS - STRO
47%
Loosely correlated
+0.19%
ERAS - STRO
45%
Loosely correlated
-1.41%
ALGS - STRO
44%
Loosely correlated
+8.77%
TRDA - STRO
43%
Loosely correlated
+2.87%
XENE - STRO
42%
Loosely correlated
+1.62%
More